NIKA PHARMACEUTICALS Business Summary

Nika Pharmaceuticals, Inc. (OTCQB: NIKA) operates as a specialty pharmaceutical company focused on the development, manufacturing, and global distribution of treatments for HIV/AIDS, Hepatitis B and C, and other immune-related diseases. The company’s revenue model is transitioning from development-stage licensing to a high-volume manufacturing and distribution framework, anchored by its flagship ITV-1 (Inactivated Pepsin Fraction) injection for HIV/AIDS. Nika generates value through exclusive multi-billion-euro distribution agreements in emerging markets, including Nigeria, Ukraine, and the MENA region, while its subsidiary, Nika Europe, is finalizing a state-of-the-art GMP-compliant production facility in Bulgaria slated for completion in Q1 2026. Within the competitive landscape, Nika contends with specialty players such as LENZ Therapeutics, SNDL Inc., and Eton Pharmaceuticals, positioning itself as a vertically integrated, low-cost provider targeting underserved international populations with life-saving generics and proprietary immunotherapies. The company is led by Chairman and CEO Dimitar Slavchev Savov, a veteran entrepreneur with over 25 years of experience in pharmaceutical project funding and a background as the founder of Elpida 3, one of Bulgaria’s first private petrol enterprises. Savov, who also serves as CFO and President, holds a majority stake in the firm and oversees its strategic pivot toward self-sustained manufacturing. He is supported by Secretary and Director Clifford Redekop, a former Canadian Navy officer and commercial real estate developer with expertise in scaling corporate expansions and public market transitions. While the company maintains a lean executive structure, its board-level oversight is concentrated under Savov and Redekop, who orchestrated the 2022 acquisition and rebranding of the entity to focus on humanitarian-driven pharmaceutical access.